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Abstract
Background: Cases of impaired renal function have been reported in patients who had been
treated with both zoledronic acid and thalidomide for myeloma. Hence, we conducted a safety
study of zoledronic acid and thalidomide in myeloma patients participating in a trial of maintenance
therapy.
Methods: Twenty-four patients who were enrolled in a large randomized trial of thalidomide vs
no thalidomide maintenance therapy for myeloma, in which all patients also received zoledronic
acid, were recruited to a pharmacokinetic and renal safety sub-study, and followed for up to 16
months.
Results: No significant differences by Wilcoxon rank-sum statistic were found in zoledronic acid
pharmacokinetics or renal safety for up to 16 months in patients randomized to thalidomide or not.
Conclusion: In myeloma patients receiving maintenance therapy, the combination of zoledronic
acid and thalidomide appears to confer no additional renal safety risks over zoledronic acid alone.
Background
Modern therapy of multiple myeloma (MM) combines
treatments to induce disease response (e.g. thalidomide,
corticosteroids and cytotoxic agents) with supportive care
to prevent bone and infective complications (e.g. bisphos-
phonates and antibiotics). However, combining agents
might cause interactions that increase toxicity or lessen
efficacy. Case reports suggested that MM patients receiving
zoledronic acid combined with thalidomide had higher
risks of renal impairment [1]. Hence, the United States'
Food and Drug Administration requested that Novartis
(manufacturer of zoledronic acid) conduct a study to look
for pharmacokinetic interaction between zoledronic acid
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and thalidomide, and to monitor renal safety of MM
patients receiving both drugs.
The Australasian Leukaemia and Lymphoma Group
(ALLG) was conducting a large (>200 patients), rand-
omized clinical trial (ALLG MM6) in MM patients, who
had received high-dose therapy and autologous stem cell
transplantation (ASCT), to ascertain the efficacy and
safety of thalidomide and prednisolone maintenance
therapy compared to prednisolone maintenance therapy
post-transplantation. All patients were scheduled to
receive adjunctive zoledronic acid intravenously on a 4th-
weekly basis. The ALLG agreed to incorporate a safety sub-
study into the ALLG MM6 study to assess the pharmacok-
inetics of zoledronic acid and to monitor renal function in
patients randomized to receive prednisolone and
zoledronic acid alone or in combination with thalido-
mide, for up to 16 months.
Methods
From two Australian hospitals (The Alfred Hospital, Mel-
bourne and The Royal Melbourne Hospital) participating
in the ALLGMM6 study, a sample of 24 patients was
enrolled in this sub-study, with institutional ethical
approval and informed consent. All patients entered the
study 6–7 weeks after high-dose therapy and ASCT for
MM. Twelve patients were randomized to Arm 1: Thalido-
mide (100 mg nocte for 14 days, then 200 mg nocte to
end of study, if tolerated) and prednisolone (50 mg orally
on alternate days) in conjunction with zoledronic acid (4
mg intravenously every 4 weeks) and 12 were randomized
to Arm 2: prednisolone and zoledronic acid.
Patients' ages ranged from 41–68, with a median of 60 in
Arm 1 and 57 in Arm 2. There were 7 males and 5 females
in each Arm. No patient had progressive myeloma, ECOG
score > 2, renal, hepatic or severe marrow impairment at
study entry. All patients agreed to precautions related to
teratogenicity.
Thalidomide was provided as 50 mg tablets by Pharmion
Pty. Ltd. Zoledronic acid was provided as 4 mg concen-
trated liquid in vials, to be made up to 100 ml for intrave-
nous infusion over 15 minutes.
For renal safety monitoring, prior to each zoledronic acid
infusion, patients' serum creatinines were checked, and
any adverse events potentially related to zoledronic acid,
thalidomide or prednisolone were collected for up to 16
months on study.
For the pharmacokinetic study, venous blood samples (3
mL in heparinized tubes) were drawn from patients' arms
contra-lateral to the site of zoledronic acid infusions or
from central venous lines at the following times: Prior to
the 1st and 2nd doses of zoledronic acid (on Days 1 and 29)
and 1, 2, 4, 8, 24 and 48 hours after the 1st and 2nd doses.
Samples were centrifuged for 15 minutes at 2000 × G, and
the plasma transferred into a labelled tube that was frozen
below -20C. All pharmacokinetic samples were shipped in
dry ice to a central laboratory (Novartis Pharma AG, Rueil-
Malmaison, France) for analysis performed by a sensitive
radioimmunoassay for zoledronic acid [2].
One patient (from Arm 1) was excluded from analysis
because their pre-dose sample contained zoledronic acid,
and the reasons for this finding were unclear. There were
also five missing samples (3 from Arm 1 and 2 from Arm
2) for post-zoledronic acid pharmacokinetic analysis on
Day 29.
Non-parametric Wilcoxon rank-sum statistics were used
(by Covance Pty. Ltd, Canberra, Australia) to compare
non-compartmental pharmacokinetics (Cmax and AUC)
of each zoledronic acid infusion in patients who did or
did not also receive thalidomide. A parametric repeated-
measures t-test analysis was also conducted to assess PK
differences over 1st  and 2nd  infusions – although no
change in plasma PK of zoledronic acid was seen with
subsequent doses in an earlier (non-combination) PK
study [3]. The study was powered with 12 patients in each
group to have 80% chance of detecting (with p = 0.05) a
43% difference in PK of zoledronic acid in conjunction
with thalidomide, based on 27% interpatient variability
of Cmax for zoledronic acid in an earlier study [4].
Results
Pharmacokinetic analyses
Mean zoledronic acid plasma concentrations over 24
hours after infusion #1 in patients receiving zoledronic
acid in combination with thalidomide and prednisolone
(Arm 1; n = 11) or with prednisolone alone (Arm 2; n =
12) are shown in Figure 1. Mean Cmax after infusion #1
was 462 (± 135) ng/mL in Arm 1 and 409 (± 142) ng/mL.
Mean AUC(0–24 hr) was 639 (± 86) ng.h/mL in Arm 1
and 651 (± 140) ng.h/mL in Arm 2. Similar figures were
obtained after infusion #2 (not shown). No differences
were statistically significant by t-test (p = 0.05).
Renal safety
Mean serum creatinine values for up to 16 infusions of
zoledronic acid are shown in Figure 2. Again no differ-
ences between patients in Arm 1 (zoledronic acid, thalid-
omide and prednisolone) and Arm 2 (zoledronic acid
with prednisolone alone) were statistically significant.
Patients' creatinine clearance (calculated from serum cre-
atinine using Cockcroft & Gault formula) for arms 1 and
2 showed mean (SD) values of 104 +/- 27 mL/min (n =
11) and 106 +/- 27 mL/min (n = 12), respectively, at base-
line and 99 +/- 20 mL/min (n = 5) and 100 +/- 20 (n = 4),BMC Clinical Pharmacology 2008, 8:2 http://www.biomedcentral.com/1472-6904/8/2
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respectively, after 13 infusions. The model estimated dif-
ference between arms 1 and 2, taking into account infu-
sion number and any interaction between treatment arms
and infusion, was 0.46 mL/min (P = 0.60), supporting the
conclusion of no effect on renal function by the addition
of thalidomide to the zoledronic acid treatment regimen.
Withdrawals from the sub-study were no different
between Arms 1 and 2, and largely due to progressive dis-
ease.
Discussion
This pharmacokinetic and renal safety sub-study of the
combination of zoledronic acid with thalidomide and
prednisolone in MM patients shows no likely PK interac-
tion between zoledronic acid and thalidomide (at doses
up to 200 mg/day). There was also no detectable increase
in serum creatinine in patients receiving combined ther-
apy for up to 16 months, unlike in previous case reports
[1].
MM patients who either a) do not receive concomitant
corticosteroid therapy, b) receive higher doses of thalido-
mide than 200 mg/day, or c) have underlying or intercur-
rent renal impairment could have interactions that were
not detected in this safety sub-study. Nevertheless, the
absence of PK interaction or renal impairment seen in this
safety sub-study is reassuring, given recent widespread
prescription of both thalidomide and zoledronic acid in
MM patients.
Conclusion
In myeloma patients receiving maintenance therapy, the
combination of zoledronic acid and thalidomide appears
to confer no additional renal safety risks over zoledronic
acid alone.
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a: Means (± standard deviation) of plasma concentrations of  zoledronic acid after 1st infusion in Arm1 (n = 11) patients  who received zoledronic acid, thalidomide and prednisolone Figure 1
a: Means (± standard deviation) of plasma concentra-
tions of zoledronic acid after 1st infusion in Arm1 (n = 
11) patients who received zoledronic acid, thalido-
mide and prednisolone. b: Means (± standard deviation) 
of plasma concentrations of zoledronic acid after 1st infusion 
in Arm2 (n = 12) patients who received zoledronic acid 
alone.
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Means (± standard deviations) of serum creatinines prior to (up to 16) infusions of zoledronic acid in patients on Arm1 (dia- monds) [receiving zoledronic acid, thalidomide and prednisolone] and Arm 2 (triangles) [receiving zoledronic acid alone] Figure 2
Means (± standard deviations) of serum creatinines prior to (up to 16) infusions of zoledronic acid in patients 
on Arm1 (diamonds) [receiving zoledronic acid, thalidomide and prednisolone] and Arm 2 (triangles) [receiv-
ing zoledronic acid alone]. Numbers of patients receiving each infusion are also shown, by reference to the scale on the 
right side.
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